Retinal Detachment
Conditions
Brief summary
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to investigate: how will pseudophakic patients respond in terms of objective and subjective outcomes, when treated with Dextenza compared to topical prednisolone acetate following gas bubble repair and laser for RD.
Detailed description
Subjects who have given informed consent and determined to be eligible at screening will be randomized in a 1:1 ratio to DEXTENZA (placed once in the lower punctum) or the use of topical Prednisolone acetate 1% drops (four times daily). They will be observed for a period of 3-months for both pain and inflammation of the eye.
Interventions
DRUGDextenza
Intracanalicular sustained release dexamethasone insert 0.4 mg
DRUGPrednisolone Acetate
Topical Prednisolone acetate 1% ophthalmic suspension
Sponsors
Ocular Therapeutix, Inc.
Midwest Eye Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pseudophakic * Retinal Detachment * Age 18 years and older * Scheduled for gas bubble repair and laser surgery following retinal detachment * Willing and able to comply with clinic visits and study related procedures * Willing and able to sign the informed consent form
Exclusion criteria
* Patients under the age of 18. * Pregnancy (must be ruled out in women of child-bearing age with pregnancy test) * Active infectious systemic disease * Active infectious ocular or extraocular disease * Obstructed nasolacrimal duct in the study eye(s) * Hypersensitivity to dexamethasone * Patients being treated with immunomodulating agents in the study eye(s) * Patients being treated with immunosuppressants and/or oral steroids * Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in pain score | 30 Days | Average change in pain based on whats reported on the Ocular Pain Assessment |
| Post-op pain scores | 30 Days | Ocular Pain Assessment: Measured on a scale from 0-10 where 0 (minimum) is no pain and 10 (maximum) is extreme pain. High reported pain means a worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in anterior chamber cell and flare score | 30 days | Post op inflammation scores as measured on a scale of 0-4: Anterior Chamber Cell Count (Absence of cell to be defined as a grade of: 0-0.5, 4 being the maximum) and Anterior Chamber Flare Score (0 is the minimum, and 4 is the maximum). High reported cell and flare means a worse outcome. |
| Cystoid Macular Edema | 30 days | Amount of central thickness macular swelling as measured by Optical Coherence Tomography (OCT) |
| Best Corrected Visual Acuity | 90 days | As measured on ETDRS |
| Physician Ease of Dextenza insertion | Day 1 | The investigator will grade the level of ease of insertion of the intracanalicular insert on a 0 to 10-point (0 being the minimum and 10 being the maximum) scale with 0 being very easy insertion and 10 being very hard. Difficult insertion means a worse outcome. |
Countries
United States
Outcome results
None listed